Myocardial perfusion improvement (MPI)

Myocardial perfusion improvement is not a single molecular target but rather a physiological process and primary therapeutic objective in the management of ischemic heart disease. It refers to the enhancement of blood flow to the heart muscle (myocardium) to ensure adequate delivery of oxygen and nutrients relative to metabolic demand. This outcome is typically pursued in the context of coronary artery disease, where atherosclerosis or vasospasm restricts flow, leading to angina or myocardial infarction. Clinically, this improvement is achieved by targeting various molecular pathways, such as the activation of Adenosine A2A receptors to induce vasodilation, the use of organic nitrates to provide nitric oxide for smooth muscle relaxation, or the inhibition of calcium channels to reduce vascular resistance. Because it describes a clinical endpoint or a systemic effect rather than a specific protein, it is categorized as a therapeutic goal. Monitoring of myocardial perfusion is standard in cardiology using imaging modalities like SPECT, PET, or cardiac MRI to assess the efficacy of pharmacological or surgical interventions.

Other names

Coronary blood flow enhancementMyocardial blood flow restorationImproved myocardial oxygen delivery

Improving myocardial perfusion is achieved through various mechanisms including the induction of coronary vasodilation (via nitric oxide donation or adenosine receptor activation), reduction of microvascular resistance, and decreasing myocardial oxygen demand through negative inotropic or chronotropic effects.